Renal Cell Carcinoma Education
Renal cell carcinoma has multiple frontline immunotherapy-TKI combinations with evolving data on sequencing and patient selection. Knowledge Med sessions use interactive case simulations to help community providers navigate these complex treatment decisions confidently.
Non-promotional, independently reviewed sessions led by faculty from Johns Hopkins, Columbia, Mount Sinai, and other leading academic medical centers.
What Providers Navigate
Physicians managing renal cell carcinoma face evolving treatment decisions that interactive, independently reviewed education can help address.
- Choosing among multiple IO-TKI and IO-IO frontline combinations
- Applying IMDC risk stratification to treatment selection
- Sequencing TKIs and managing acquired resistance
- Treating non-clear cell and sarcomatoid histologies
What Sessions Cover
Knowledge Med RCC sessions use interactive case simulations to address these topics and more.
- First-line IO-TKI combinations: selecting the right regimen
- Risk-stratified treatment approaches in advanced RCC
- Second-line and beyond: sequencing after IO-TKI progression
- Emerging agents: HIF-2α inhibitors and novel combinations
Interactive RCC Sessions
Case Simulations
Work through realistic renal cell carcinoma patient cases with expert faculty, making treatment decisions at each stage.
Live Polling
See how your clinical decisions compare to peers in real time — revealing practice patterns and knowledge gaps.
Personalized Report
Receive a session summary with your individual responses, peer benchmarks, and key RCC clinical takeaways.
More Solid Tumor Sessions
Knowledge Med offers interactive sessions across many indications — these are just some of the areas we cover.
Metastatic Colorectal Cancer
mCRC — Biomarker-driven first-line therapy selection in mCRC
HER2-Positive Breast Cancer
HER2+ — First-line treatment selection in HER2+ metastatic breast cancer
Metastatic Breast Cancer
mBC — First-line endocrine-based therapy selection in HR+/HER2- mBC
Triple-Negative Breast Cancer
TNBC — Immunotherapy in first-line metastatic TNBC: patient selection and regimens
Join a RCC Session
Third-party, non-promotional renal cell carcinoma education led by faculty from leading academic medical centers. Case simulations. Live polling. Personalized insights.
Join a Session